Eric Bruckert Articles
Are we doing any better with familial hypercholesterolaemia care?
Professor Eric Bruckert, Pitié-Salpêtrière Hospital, Paris, France In the last 5 years, there has been a drive to improve the care of familial hypercholesterolaemia (FH), one of the most common inherited disorders, affecting as many as 1 in 200-250 individuals worldwide.1,2 This follows on from…
read more »
ODYSSEY 78 week HeFH data: Clinical perspectives
PCSK9 monoclonal antibody therapy has been shown to be highly efficacious in patients with heterozygous familial hypercholesterolaemia (FH, inherited high cholesterol). However, as patients will require treatment in the long-term, efficacy and safety data are needed. The recent publication of 78 week data from the…
read more »
FH in the statin era: we need to do better
Despite the availability of generic statin therapy, cardiovascular disease accounts for 50% of all deaths in FH patients. Clinicians need to do better, argues Eric Bruckert, Institut E3M et IHU cardiométabolique (ICAN), Hôpital Pitié Salpêtrière, Paris, France. Familial hypercholesterolemia (FH) is a severe condition, which…
read more »
